{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:39:55Z","timestamp":1790609995468,"version":"4.1.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T00:00:00Z","timestamp":1720828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.phrs.2024.107310","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T04:11:35Z","timestamp":1721880695000},"page":"107310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Leo Sternbach and the benzodiazepines 60 years on: A revolutionary treatment for anxiety disorders"],"prefix":"10.1016","volume":"207","author":[{"given":"Larissa","family":"Junkes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro V.","family":"Mendlowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Shader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio E.","family":"Nardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2024.107310_bib1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1001\/archpsyc.1988.01800290027004","article-title":"Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment","volume":"45","author":"Ballenger","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107310_bib2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF00464571","article-title":"Alprazolam in the treatment of generalized anxiety and panic disorders: a double-blind placebo-controlled study","volume":"77","author":"Chouinard","year":"1982","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.phrs.2024.107310_bib3","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1055\/s-2007-1014489","article-title":"Lorazepam vs. alprazolam in the treatment of panic disorder","volume":"23","author":"Schweizer","year":"1990","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.phrs.2024.107310_bib4","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1590\/S0100-879X2011000400015","article-title":"Psychopharmacotherapy of panic disorder: 8 week randomized trial with clonazepam and paroxetine","volume":"44","author":"Nardi","year":"2011","journal-title":"Braz. J. Med Biol. Res"},{"key":"10.1016\/j.phrs.2024.107310_bib5","first-page":"418","article-title":"Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam","volume":"50","author":"Charney","year":"1989","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107310_bib6","first-page":"69","article-title":"Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder","volume":"52","author":"Tesar","year":"1991","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107310_bib7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00004714-198902000-00005","article-title":"Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks","volume":"9","author":"Munjack","year":"1989","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2024.107310_bib8","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/JCP.0b013e31822d0012","article-title":"The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder","volume":"31","author":"Moylan","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2024.107310_bib9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0022-3956(90)90032-L","article-title":"Efficacy of benzodiazepines in panic disorder and agoraphobia","volume":"24","author":"Ballenger","year":"1990","journal-title":"J. Psychiatr. Res"},{"key":"10.1016\/j.phrs.2024.107310_bib10","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1176\/ajp.149.11.1556","article-title":"Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia","volume":"149","author":"Lesser","year":"1992","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107310_bib11","first-page":"349","article-title":"Diazepam versus alprazolam for the treatment of panic disorder","volume":"57","author":"Noyes","year":"1996","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107310_bib12","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2174\/1871527313666140612125028","article-title":"Current pharmacological interventions in panic disorder","volume":"13","author":"Freire","year":"2014","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.phrs.2024.107310_bib13","first-page":"353","article-title":"Clonazepam for the treatment of panic disorder","volume":"14","author":"Nardi","year":"2013","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.phrs.2024.107310_bib14","article-title":"Pharmacological treatments in panic disorder in adults: a network meta-analysis","volume":"11","author":"Guaiana","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.phrs.2024.107310_bib15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11920-016-0668-3","article-title":"Long-Term Pharmacological Treatments of Anxiety Disorders: An Updated Systematic Review","volume":"18","author":"Perna","year":"2016","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.phrs.2024.107310_bib16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00004714-198406000-00002","article-title":"Alprazolam and diazepam in the treatment of generalized anxiety","volume":"4","author":"Elie","year":"1984","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2024.107310_bib17","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1600-0447.1986.tb06268.x","article-title":"Bromazepam and lorazepam in generalized anxiety: a placebo-controlled study with measurements of drug plasma concentrations","volume":"74","author":"Fontaine","year":"1986","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.phrs.2024.107310_bib18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/bod.2510090504","article-title":"Placebo-controlled comparative study of the anxiolytic activity and pharmacokinetics of oral and sublingual lorazepam in generalized anxiety","volume":"9","author":"Spenard","year":"1988","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.phrs.2024.107310_bib19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00004714-200102000-00011","article-title":"Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group","volume":"21","author":"M\u00f6ller","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2024.107310_bib20","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00004714-199606000-00002","article-title":"Treatment, discontinuation, and psychomotor effects of diazepam in women with generalized anxiety disorder","volume":"16","author":"Pourmotabbed","year":"1996","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2024.107310_bib21","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/YIC.0b013e32832dceb9","article-title":"The efficacy of pregabalin and benzodiazepines in generalized anxiety disorder presenting with high levels of insomnia","volume":"24","author":"Montgomery","year":"2009","journal-title":"Int Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2024.107310_bib22","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/BF02244440","article-title":"Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder","volume":"105","author":"Enkelmann","year":"1991","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.phrs.2024.107310_bib23","article-title":"Galphimine-B Standardized Extract versus Alprazolam in Patients with Generalized Anxiety Disorder: A Ten-Week, Double-Blind, Randomized Clinical Trial","volume":"30","author":"Romero-Cerecero","year":"2019","journal-title":"Biomed. Res Int"},{"key":"10.1016\/j.phrs.2024.107310_bib24","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.pscychresns.2015.06.016","article-title":"Temporal profile of brain response to alprazolam in patients with generalized anxiety disorder","volume":"233","author":"Brown","year":"2015","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.phrs.2024.107310_bib25","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/j.1875-9114.1985.tb03430.x","article-title":"Comparison of buspirone and diazepam in generalized anxiety disorder","volume":"5","author":"Jacobson","year":"1985","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.phrs.2024.107310_bib26","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/00004714-199708000-00006","article-title":"Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial","volume":"17","author":"Rickels","year":"1997","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2024.107310_bib27","first-page":"9","article-title":"Pharmacotherapy of generalized anxiety disorder","volume":"63","author":"Rickels","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107310_bib28","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1177\/0269881107077355","article-title":"Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials","volume":"21","author":"Martin","year":"2007","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.phrs.2024.107310_bib29","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00004714-199312000-00008","article-title":"Treatment of social phobia with clonazepam and placebo","volume":"13","author":"Davidson","year":"1993","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2024.107310_bib30","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.eurpsy.2008.05.004","article-title":"A pilot study of clonazepam versus psychodynamic group therapy plus clonazepam in the treatment of generalized social anxiety disorder","volume":"23","author":"Knijnik","year":"2008","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107310_bib31","first-page":"244","article-title":"Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder","volume":"65","author":"Seedat","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107310_bib32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3109\/15622970009150563","article-title":"A review of 19 double-blind placebo-controlled studies in social anxiety disorder (social phobia)","volume":"1","author":"Versiani","year":"2000","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107310_bib33","first-page":"50","article-title":"Benzodiazepines and anticonvulsants for social phobia (social anxiety disorder)","volume":"62","author":"Jefferson","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107310_bib34","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1176\/appi.ajp.2013.12101353","article-title":"A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder","volume":"171","author":"Pollack","year":"2014","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107310_bib35","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1034\/j.1600-0447.108.s417.7.x","article-title":"Pharmacotherapy of social phobia","volume":"417","author":"Davidson","year":"2003","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.phrs.2024.107310_bib36","first-page":"20","article-title":"Pharmacotherapy of social anxiety disorder: what does the evidence tell us?","volume":"67","author":"Davidson","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107310_bib37","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0006-3223(01)01294-X","article-title":"Pharmacotherapy of social anxiety disorder","volume":"51","author":"Blanco","year":"2002","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107310_bib38","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1017\/neu.2020.6","article-title":"Pharmacological treatments for social anxiety disorder in adults: a systematic review and network meta-analysis","volume":"32","author":"Williams","year":"2020","journal-title":"Acta Neuropsychiatr."},{"key":"10.1016\/j.phrs.2024.107310_bib39","unstructured":"FDA, FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class, 2020. \u3008https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class\u3009 (accessed May 26, 2024)."},{"key":"10.1016\/j.phrs.2024.107310_bib40","unstructured":"Fact.M.R., Benzodiazepine Drugs Market Analysis, 2022."},{"key":"10.1016\/j.phrs.2024.107310_bib41","unstructured":"J. Febrer, Leo Henryk Sternbach (1908-2005), \u3008Http:\/\/Www.Historiadelamedicina.Org\/Sternbach.Html\u3009 82 (2022) 475\u2013480. \u3008http:\/\/www.historiadelamedicina.org\/sternbach.html\u3009."},{"key":"10.1016\/j.phrs.2024.107310_bib42","series-title":"Good Chemistry: The Life and Legacy of Valium Inventor Leo Sternbach","author":"Baenninger","year":"2004"},{"key":"10.1016\/j.phrs.2024.107310_bib43","first-page":"475","article-title":"In memory of three pioneers","volume":"9","author":"Ban","year":"2006","journal-title":"Int. J. Neuropsychopharmacol. \/ Off. Sci. J. Coll. Int. Neuropsychopharmacol. (CINP"},{"key":"10.1016\/j.phrs.2024.107310_bib44","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/S0140-6736(05)67588-5","article-title":"Leo H Sternbach","volume":"366","author":"Oransky","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2024.107310_bib45","unstructured":"P. Sullivan, Inventor of Valium, Once the Most Often Prescribed Drug, Dies, Washington Post (2005)."},{"key":"10.1016\/j.phrs.2024.107310_bib46","doi-asserted-by":"crossref","unstructured":"L.H. Sternbach, The Discovery of Librium, 1972.","DOI":"10.1007\/BF01965860"},{"key":"10.1016\/j.phrs.2024.107310_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/jm00187a001","article-title":"The Benzodiazepine Story","volume":"22","author":"Sternbach","year":"1979","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2024.107310_bib48","article-title":"The benzodiazepine story","author":"Casy","year":"1978","journal-title":"Prog. Drug Res."},{"key":"10.1016\/j.phrs.2024.107310_bib49","unstructured":"Nuss P., Sanger D., Ansiol\u00edticos (II). La consolidaci\u00f3n de la era ansiol\u00edtica: el desarrollo y la introducci\u00f3n cl\u00ednica de las benzodiazepinas, in: F. L\u00f3pez-Munoz, C. \u00c1lamo (Eds.), Historia de La Psicofarmacolog\u00eda, Editorial M\u00e9dica Panamericana, Madrid, 2007: pp. 808\u2013824."},{"key":"10.1016\/j.phrs.2024.107310_bib50","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.janxdis.2011.01.002","article-title":"The discovery of chlordiazepoxide and the clinical introduction of benzodiazepines: Half a century of anxiolytic drugs","volume":"25","author":"L\u00f3pez-Mu\u00f1oz","year":"2011","journal-title":"J. Anxiety Disord."},{"key":"10.1016\/j.phrs.2024.107310_bib51","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/jama.1960.63020110010011","article-title":"Methaminodiazepoxide","volume":"172","author":"Harris","year":"1960","journal-title":"J. Am. Med Assoc."},{"key":"10.1016\/j.phrs.2024.107310_bib52","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4140\/TCP.n.2013.538","article-title":"The History of Benzodiazepines","volume":"28","author":"Wick","year":"2013","journal-title":"Consult. Pharm."},{"key":"10.1016\/j.phrs.2024.107310_bib53","unstructured":"C. Heather Ashton, Benzodiazepines: How They Work and How to Withdraw, Benzodiazepine Information Coalition, Newcastle, 2019."},{"key":"10.1016\/j.phrs.2024.107310_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2023.109418","article-title":"Alleviating anxiety and taming trauma: novel pharmacotherapeutics for anxiety disorders and posttraumatic stress disorder","volume":"226","author":"Singewald","year":"2023","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2024.107310_bib55","doi-asserted-by":"crossref","first-page":"9","DOI":"10.21472\/bjbs.061202","article-title":"GABAergic transmission and modulation of anxiety: A review on molecular aspects","volume":"6","author":"Gomes","year":"2019","journal-title":"Braz. J. Biol. Sci."},{"key":"10.1016\/j.phrs.2024.107310_bib56","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41401-018-0185-5","article-title":"Human pharmacology of positive GABA-A subtype-selective receptor modulators for the treatment of anxiety","volume":"40","author":"Chen","year":"2019","journal-title":"Acta Pharm. Sin."},{"key":"10.1016\/j.phrs.2024.107310_bib57","doi-asserted-by":"crossref","first-page":"19343","DOI":"10.1074\/jbc.M113.479725","article-title":"Specificity of Intersubunit General Anesthetic-binding Sites in the Transmembrane Domain of the Human \u03b11\u03b23\u03b32 \u03b3-Aminobutyric Acid Type A (GABAA) Receptor","volume":"288","author":"Chiara","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2024.107310_bib58","unstructured":"Fryer R.I., Bicyclic Diazepines: Diazepines with an Additional Ring, 2009."},{"key":"10.1016\/j.phrs.2024.107310_bib59","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1023\/A:1006943009192","article-title":"Metabolism of anxiolytics and hypnotics: Benzodiazepines, buspirone, zoplicone, and zolpidem","volume":"19","author":"Chouinard","year":"1999","journal-title":"Cell Mol. Neurobiol."},{"key":"10.1016\/j.phrs.2024.107310_bib60","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1039\/D2RA06045K","article-title":"Synthetic aspects of 1,4- and 1,5-benzodiazepines using o-phenylenediamine: a study of past quinquennial","volume":"13","author":"Teli","year":"2023","journal-title":"RSC Adv."},{"key":"10.1016\/j.phrs.2024.107310_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103668","article-title":"Recent advances in synthesis and medicinal chemistry of benzodiazepines","volume":"97","author":"Arora","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.phrs.2024.107310_bib62","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/0269881106072343","article-title":"Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers","volume":"21","author":"de Haas","year":"2007","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.phrs.2024.107310_bib63","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/0269881107082108","article-title":"Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA (A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers","volume":"22","author":"de Haas","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.phrs.2024.107310_bib64","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1177\/0269881108092595","article-title":"The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A alpha2,3 selective agonist, in comparison with lorazepam in healthy volunteers","volume":"23","author":"de Haas","year":"2009","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.phrs.2024.107310_bib65","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/bcp.12413","article-title":"The central nervous system effects of the partial GABA-A\u03b12,3-selective receptor modulator AZD7325 in comparison with lorazepam in healthy males","volume":"78","author":"Chen","year":"2014","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.phrs.2024.107310_bib66","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/JCP.0000000000000251","article-title":"AZD6280, a novel partial \u03b3-aminobutyric acid A receptor modulator, demonstrates a pharmacodynamically selective effect profile in healthy male volunteers","volume":"33","author":"Chen","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2024.107310_bib67","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/0269881115620435","article-title":"NS11821, a partial subtype-selective GABAA agonist, elicits selective effects on the central nervous system in randomized controlled trial with healthy subjects","volume":"30","author":"Zuiker","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.phrs.2024.107310_bib68","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1054-3589(08)57004-9","article-title":"receptor modulation yields a novel pharmacological profile: the design and development of TPA023","volume":"57","author":"Atack","year":"2009","journal-title":"Adv. Pharm."},{"key":"10.1016\/j.phrs.2024.107310_bib69","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/bs.apha.2014.10.001","article-title":"Behavioral functions of GABAA receptor subtypes-the Zurich experience","volume":"72","author":"Crestani","year":"2015","journal-title":"Adv. Pharm."},{"key":"10.1016\/j.phrs.2024.107310_bib70","doi-asserted-by":"crossref","DOI":"10.1007\/s11920-015-0564-2","article-title":"Psychopharmacological Strategies in the Management of Posttraumatic Stress Disorder (PTSD): What Have We Learned?","volume":"17","author":"Bernardy","year":"2015","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.phrs.2024.107310_bib71","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1016\/j.tetlet.2016.07.005","article-title":"Deep eutectic solvent as a highly efficient reaction media for the one-pot synthesis of benzo-fused seven-membered heterocycles","volume":"57","author":"Shaabani","year":"2016","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.phrs.2024.107310_bib72","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.arabjc.2015.01.007","article-title":"Synthesis and biological evaluation of some novel pyrazole, isoxazole, benzoxazepine, benzothiazepine and benzodiazepine derivatives bearing an aryl sulfonate moiety as antimicrobial and anti-inflammatory agents","volume":"12","author":"Kendre","year":"2019","journal-title":"Arab. J. Chem."},{"key":"10.1016\/j.phrs.2024.107310_bib73","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1039\/C8OB02903B","article-title":"A catalyst-free four-component domino reaction for the synthesis of functionalized 3-acyl-1,5-benzodiazepines","volume":"17","author":"Sun","year":"2019","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.phrs.2024.107310_bib74","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0160-3450(16)32158-4","article-title":"Valium & values","volume":"23","author":"Kilwein","year":"1983","journal-title":"Am. Pharm."},{"key":"10.1016\/j.phrs.2024.107310_bib75","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.eurpsy.2011.11.003","article-title":"Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal","volume":"28","author":"Dell\u2019osso","year":"2013","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107310_bib76","unstructured":"Pearce J., Leo Sternbach, 97, Valium Creator Dies, The New York Times (2005)."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366182400255X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366182400255X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T23:13:56Z","timestamp":1724454836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104366182400255X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":76,"alternative-id":["S104366182400255X"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107310","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leo Sternbach and the benzodiazepines 60 years on: A revolutionary treatment for anxiety disorders","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107310","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107310"}}